Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Designed to "capture the essence of classic sequencing with the flexibility of modern modular workflow", BQ-10 brings MIDI ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug. The ...

Black Friday 2025 has arrived — earlier, bigger, and sharper than ever. Whether you’re upgrading your battlestation, ...